Henlius and Promega Form IVD Collaboration for PD-1 Candidate
publication date: Aug 5, 2021
Shanghai Henlius Biotech will collaborate with Shanghai Promega to provide a companion IVD kit for serplulimab, its anti-PD-1 drug. Henlius will develop Promega's OncoMate™ MSI Dx Analysis System to determine microsatellite instability (MSI) status in solid tumor cancers. Patients with high levels of MSA have been shown to react well to immune checkpoint inhibitors, including PD-1 therapies. Promega is a global research tools company that is headquartered in Wisconsin. Henlius, a Fosun Pharma spin-out, focuses on biologic drug development. More details....
Stock Symbol: (HK: 2696)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.